I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China

Ads

You May Also Like

Alliqua BioMedical Presents at the Spring 2016 SAWC Meeting

YARDLEY, Pa., April 12, 2016 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or ...

Mateon Therapeutics Reports First Quarter 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), ...